Skip to content

Effects of Inspiratory Muscle Training on Lymphedema

Effects of Inspiratory Muscle Training on Lymphedema Volume, Subcutaneous Tissue Thickness, Upper Extremity Functioning, Sleep Quality, and Quality of Life in Upper Extremity Lymphedema Treatment: a Randomized Controlled Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06521268
Enrollment
24
Registered
2024-07-25
Start date
2025-07-01
Completion date
2027-05-15
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema

Keywords

Lymphedema, Inspiratory muscle training, Decongestive treatment, Physical functioning, Sleep quality, Quality of life

Brief summary

The aim of this study is to examine the effect of inspiratory muscle training on lymphedema volume, subcutaneous tissue thickness, upper extremity functionality and sleep quality in the treatment of upper extremity lymphedema. Two groups included 24 patients with lymphedema will be divided into gropus (intervetion and control) and they will compare each other.

Detailed description

All patients will be treated 5 days a week, 4 weeks, with each session lasting 45-60 minutes. While only decongestive treatment will be applied to the control group, inspiratory muscle training will be given to the interventional group in addition to decongestive treatment. Evaluations of the patients will be made before and after of 4-week treatment program.

Interventions

OTHERInspiratory muscle training

Inspiratory muscle training

OTHERDecongestive treatment

Decongestive treatment

Sponsors

Biruni University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

randomized controlled study

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Having been diagnosed with lymphedema in the upper extremity at least 6 months ago * Having stage 2 lymphedema * Having a 2-8 cm circumference difference between the affected extremity and the healthy extremity at any reference point * Being between the ages of 18-60 * Voluntarily agreeing to participate in the study * Not having received any lymphedema treatment in the last 6 months. * Not having any physical, respiratory, neurological and/or systemic disease that would prevent participation in the treatment program.

Exclusion criteria

Having stage 1 and stage 3 lymphedema * It has been less than 6 months since the diagnosis of lymphedema was made * Being under 18 years of age and over 60 years of age * Having a circumference measurement difference of more than 8 cm and less than 2 cm at any reference point between the affected extremity and the healthy extremity * Lymphedema or elephantiasis with papilloma, hyperkeratosis * Uncontrolled hypertension, pulmonary edema, presence of serious cardiovascular disease * Presence of active metastasis * Acute inflammatory diseases

Design outcomes

Primary

MeasureTime frameDescription
Volumetric Measurementbaseline and immediately after the intervention (in the 5th week)to measure volume of the upper extremity in milliliter (increased volume compared to the normal upper extremity- increased score means worse outcome)
Measurement of Subcutaneous Tissue Thickness with Ultrasound (US)baseline and immediately after the intervention (in the 5th week)to measure thickness of the tissue (increased thickness compared to the normal upper extremity- increased score means worse outcome)

Secondary

MeasureTime frameDescription
Quick Disabilities Of the Arm,Shoulder And Hand (Quick DASH)baseline and immediately after the intervention (in the 5th week)to measure physical functioning of upper extremities (min. scorre is 0-max.score is 100- higher score means worse outcome)
Respiratory Function Testbefore and after the intervention (in the 5th week)to measure respiratory parameters (FEV1, FVC- higher score means better)
Intraoral pressure measurebefore and after the intervention (in the 5th week)to measure Intraoral Pressure parameters (MEP and MIP- higher score means better)
VISUAL ANALOG SCALE-VASbaseline and immediately after the intervention (in the 5th week)to measure swelling feel, heaviness of edema, and tension of edema (min. score is 0- max.score is10: higher score means worse outcome)
Lymph-ICFbefore and after the intervention (in the 5th week)to describe Lymphoedema Functioning, Disability And Health status of the partifcipants (min. score is 0 and max. score is 290- higher score means worse outcome)
Pittsburgh Sleep Quality Index (PSQI)before and after the intervention (in the 5th week)to measure sleep quality (min. score is 0 and max.score is 21 - higher score means worse outcome)
Lymphedema Life Impact Scale - LLISbefore and after the intervention (in the 5th week)to measure impact of lymphedema on the survivors with lymphedema (min. score is 18 and max. score is 90- higher score means worse outcome)
HAND DYNAMOMETERbaseline and immediately after the intervention (in the 5th week)to measure hand grip (in Newton- higher score means better score)

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026